Randomized clinical study evaluating the impact of 12 months aggressive (atorvastatin 80mg + ezetimibe 10mg) and standard hypolipidemic therapy on coronary atherosclerosis examined by virtual histology. Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition.